Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    MK7684-001
Previous Study | Return to List | Next Study

Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02964013
Recruitment Status : Recruiting
First Posted : November 15, 2016
Last Update Posted : July 12, 2019
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
This is a safety, efficacy, and pharmacokinetics study of MK-7684 as monotherapy and in combination with pembrolizumab (MK-3475) or pembrolizumab plus pemetrexed and carboplatin in adults with metastatic solid tumors for which there is no available therapy that is expected to convey clinical benefit. Part A of this study is a dose escalation and confirmation phase to estimate the recommended Phase 2 dose (RPTD) for MK-7684 monotherapy or in combination with pembrolizumab, pemetrexed, and carboplatin. Part A will also evaluate the anti-tumor activity of MK-7684 in combination with pembrolizumab plus pemetrexed and carboplatin in participants with non-small cell lung cancer (NSCLC) and MK-7684 (at two dose levels) in combination with pembrolizumab in Japanese participants with gastric cancer. Part B will evaluate the anti-tumor activity of MK-7684 at the RPTD when used as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors in a non-randomized study design. Part B will also evaluate 2 doses of MK-7684 in combination with pembrolizumab in participants with programmed death 1 (PD-1) treatment naïve cancer using a 1:1 randomized study design. The primary hypothesis is that MK-7684 administered as monotherapy or in combination with pembrolizumab is safe when administered at the RPTD.

Condition or disease Intervention/treatment Phase
Neoplasms Biological: MK-7684 Biological: pembrolizumab Drug: pemetrexed Drug: carboplatin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 392 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Actual Study Start Date : December 13, 2016
Estimated Primary Completion Date : June 3, 2022
Estimated Study Completion Date : June 3, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MK-7684
During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of MK-7684 on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD has been established. The RPTD will be established based on the number of dose limiting toxicities (DLTs) at each dose level. Once the RPTD is established, participants will continue receiving the RPTD of MK-7684 on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Biological: MK-7684
Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Experimental: MK-7684+pembrolizumab (pembro)
During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD of MK-7684 has been established. The RPTD will be established based on the number of DLTs at each dose level. Once the RPTD of MK-7684 is established, participants will continue receiving the RPTD of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Biological: MK-7684
Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Biological: pembrolizumab
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
Other Name: KEYTRUDA®

Experimental: Advanced solid tumor cohort
Participants will receive the RPTD of MK-7684 monotherapy or the RPTD of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Biological: MK-7684
Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Biological: pembrolizumab
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
Other Name: KEYTRUDA®

Experimental: Randomized dose 1 comparison cohort
Participants will be randomized to receive a fixed dose (Dose 1) of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Biological: MK-7684
Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Biological: pembrolizumab
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
Other Name: KEYTRUDA®

Experimental: Randomized dose 2 comparison cohort
Participants will be randomized to receive a fixed dose (Dose 2) of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Biological: MK-7684
Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Biological: pembrolizumab
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
Other Name: KEYTRUDA®

Experimental: MK-7684+pembro+pemetrexed+carboplatin
Participants will receive a fixed dose of MK-7684 in combination with 200 mg pembrolizumab, 500 mg/m^2 pemetrexed, and Area Under Curve (AUC) 5 mg/mL/min carboplatin on Day 1 of each 21-day infusion cycle for up to 4 cycles followed by maintenance therapy with a fixed dose of MK-7684 in combination with 200 mg pembrolizumab and 500 mg/m^2 pemetrexed on Day 1 of each 21-day infusion cycle for up to an additional 31 cycles.
Biological: MK-7684
Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Biological: pembrolizumab
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
Other Name: KEYTRUDA®

Drug: pemetrexed
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
Other Name: ALIMTA®

Drug: carboplatin
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
Other Name: PARAPLATIN®

Experimental: MK-7684 Dose 1 Japanese cohort
Japanese participants will be randomized to receive a fixed dose (Dose 1) of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Biological: MK-7684
Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Biological: pembrolizumab
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
Other Name: KEYTRUDA®

Experimental: MK-7684 Dose 2 Japanese cohort
Japanese participants will be randomized to receive a fixed dose (Dose 2) of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Biological: MK-7684
Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Biological: pembrolizumab
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
Other Name: KEYTRUDA®




Primary Outcome Measures :
  1. Number of Participants with Dose Limiting Toxicities (DLTs) [ Time Frame: Up to 24 Months ]

Secondary Outcome Measures :
  1. Overall Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) [ Time Frame: Up to 24 Months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • For Part A Japanese cohort added with Amendment 7: Must reside in Japan and be of Japanese descent and have adenocarcinoma of the stomach and/or gastric-esophageal junction (GEJ) that is considered inoperable and that has received, and progressed on, at least 1 prior chemotherapy regimen or human epidermal growth factor receptor 2 (HER2)/neu-targeted approved therapy (if HER2/neu-positive). In both cases, participants may be untreated or could have received and progressed on 1 prior regimen, but must not have received prior anti-PD-1/PD-L1 therapy
  • For Part A participants with NSCLC added with Amendment 7: Must have a histologically or cytologically confirmed diagnosis of stage IV (M1a or M1b per current AJCC criteria, edition 8) non-squamous NSCLC
  • For Parts A and B: Has histologically or cytologically confirmed metastatic solid tumor
  • Has measureable disease by Response Evaluation Criteria In Solid Tumors (RECIST)
  • Has an Eastern Cooperative Oncology Group performance status of 0 to 1
  • Females must not be pregnant
  • Women of childbearing potential and male participants must agree to use adequate contraception for the course of the study
  • Has provided a tumor tissue sample (archival or newly obtained core or excisional biopsy of a tumor lesion)

Exclusion Criteria:

  • Has had chemotherapy, radiation, biological cancer therapy or major surgery within 4 weeks prior to the first dose of study treatment
  • Has not recovered to Common Toxicity Criteria for Adverse Events Grade 1 or better from the adverse events due to cancer therapeutics administered more than 4 weeks prior to the first dose of study treatment
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
  • Has received previous treatment with another agent targeting the T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (TIGIT) receptor
  • Has received previous treatment with an immunomodulatory agent (e.g., anti-programmed cell death 1/ anti-programmed cell death ligand 1 or cytotoxic T-lymphocyte-associated protein 4) and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event
  • Is expected to require any other form of antineoplastic therapy while participating in the trial
  • Is on chronic systemic steroid therapy in excess of replacement doses or on any other form of immunosuppressive medication.
  • Has a history of a previous additional malignancy unless potentially curative treatment has been completed with no evidence of malignancy for 5 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has an active autoimmune disease
  • Has an active infection requiring systemic treatment
  • Has interstitial lung disease
  • Has active or past history of (non-infectious) pneumonitis requiring steroids
  • Has symptomatic ascites or pleural effusion
  • Has previously had a hematopoetic stem cell transplant or solid organ transplant
  • Is known to be human immunodeficiency virus (HIV) positive and/or known to have active chronic or acute Hepatitis B or Hepatitis C
  • Has a known psychiatric and/or substance abuse disorder that would make it difficult for the participant to cooperate with the requirements of the trial
  • Is a regular user (including recreational use) of any illicit drugs at the time of signing informed consent, or has a recent history (within the last year) of substance abuse
  • Has received a live-virus vaccine within 30 days prior to the first dose of study treatment
  • Has had hormonal cancer therapy (e.g., tamoxifen, leuprolide). within 4 weeks prior to the first dose of study treatment
  • For Part A participants with NSCLC added with Amendment 7: Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) other than an aspirin dose ≤1.3 gram per day for a 5-day period (8-day period for long-acting agents, such as piroxicam)
  • For Part A participants with NSCLC added with Amendment 7: Is unable or unwilling to take folic acid or Vitamin B12 supplementation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02964013


Contacts
Layout table for location contacts
Contact: Toll Free Number 1-888-577-8839

Locations
Layout table for location information
United States, Arizona
Call for Information (Investigational Site 0013) Recruiting
Gilbert, Arizona, United States, 85234
United States, California
Call for Information (Investigational Site 0012) Recruiting
Duarte, California, United States, 91010
United States, Colorado
Call for Information (Investigational Site 0006) Recruiting
Aurora, Colorado, United States, 80045
United States, Connecticut
Call for Information (Investigational Site 0003) Recruiting
New Haven, Connecticut, United States, 06511
United States, Michigan
Call for Information (Investigational Site 0009) Recruiting
Detroit, Michigan, United States, 48201
United States, New Jersey
Call for Information (Investigational Site 0005) Recruiting
Hackensack, New Jersey, United States, 07601
United States, North Carolina
Call for Information (Investigational Site 0011) Recruiting
Charlotte, North Carolina, United States, 28204
United States, Pennsylvania
Call for Information (Investigational Site 0010) Recruiting
Pittsburgh, Pennsylvania, United States, 15232
United States, Tennessee
Call for Information (Investigational Site 0004) Recruiting
Nashville, Tennessee, United States, 37203
United States, Texas
Call for Information (Investigational Site 0001) Recruiting
San Antonio, Texas, United States, 78229
Australia
Merck Sharp & Dohme Recruiting
North Ryde, Australia
Contact: Australian Medical Information Centre    61 2 8988 8428      
Israel
Merck Sharp & Dohme Co. Ltd. Recruiting
Hod Hasharon, Israel
Contact: Gally Teper    972-9-9533310      
Japan
MSD K.K. Recruiting
Chiyoda-Ku, Tokyo, Japan, 102-8667
Contact: Japan Call Center    81-3-6272-1957      
Korea, Republic of
MSD Korea LTD Recruiting
Seoul, Korea, Republic of, 4130
Contact: Jongho Ahn    82-2-331-2000 2015      
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT02964013     History of Changes
Other Study ID Numbers: 7684-001
MK-7684-001 ( Other Identifier: Merck Protocol Number )
First Posted: November 15, 2016    Key Record Dates
Last Update Posted: July 12, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Merck Sharp & Dohme Corp.:
Programmed Cell Death Receptor 1 (PD-1)
Programmed Cell Death Receptor Ligand 1 (PD-L1)
Programmed Cell Death Receptor Ligand 2 (PD-L2)
PD-1
PDL1
PD-L1
PD-L2

Additional relevant MeSH terms:
Layout table for MeSH terms
Carboplatin
Pembrolizumab
Pemetrexed
Antineoplastic Agents
Antineoplastic Agents, Immunological
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors